Clinical trials · Charlotte, NC
Multiple myeloma clinical trials in Charlotte
We’re tracking 28 recruiting multiple myeloma studies with a site in or near Charlotte — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies near Charlotte
- NCT06953960RecruitingPhase 1/Phase 2
Surzetoclax for multiple myeloma
This trial tests a new oral drug, surzetoclax, given alone or with other myeloma treatments, in adults whose myeloma has come back or stopped responding to treatment. It may help slow the disease and improve symptoms.
Charlotte, North CarolinaAges 18 years+ - NCT05850234RecruitingPhase 1/Phase 2
Study drug for hard-to-treat multiple myeloma after prior treatments
This Phase 1/2 study tests AZD0120 in people with multiple myeloma that has come back or is not responding to treatment. It may help by targeting the myeloma cells after you’ve already tried several standard therapies.
Charlotte, North CarolinaAges 18 years+ - NCT06297226RecruitingPhase 2
CAR T cell therapy for multiple myeloma
This trial tests a new CAR T cell therapy (arlocabtagene autoleucel) that targets a protein called GPRC5D on myeloma cells. It is for people whose multiple myeloma has come back or is not responding after trying at least four different types of treatment.
Charlotte, North CarolinaAges 18 years+ - NCT07764978RecruitingPhase 3
New drug combo for multiple myeloma without stem cell transplant
This trial tests a new drug called AZD0120 added to standard treatments for people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. It aims to see if the combination can better control the disease and improve outcomes.
Charlotte, North CarolinaAges 18 years+ - NCT02693535RecruitingPhase 2
Targeted drug testing for advanced cancer with tumor gene changes
This trial tests whether FDA-approved targeted drugs can help people with advanced cancer whose tumors have specific gene changes. It aims to match your tumor's unique genetic profile to a drug that may work better for you.
Charlotte, North CarolinaAges 12 years+ - NCT06679101RecruitingPhase 3
Belantamab combination vs standard care for newly diagnosed multiple myeloma
This trial tests a new drug combination (belantamab mafodotin plus lenalidomide and dexamethasone) against the usual treatment for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. It aims to see if the new combination works better.
Charlotte, North CarolinaAges 18 years+ - NCT06870760Recruiting
Early blood cancer detection in Charlotte firefighters
This study looks at firefighters to find early signs of blood cancers before they become serious. It aims to learn how to catch these cancers earlier, so they can be treated sooner.
Charlotte, North CarolinaAges 40–49 - NCT05552222RecruitingPhase 3
New treatment combo study for newly diagnosed multiple myeloma
This phase 3 trial tests two different drug combinations to treat newly diagnosed multiple myeloma. It may help by aiming to control the cancer without using high-dose chemotherapy and stem cell transplant for people who can’t receive that approach.
Charlotte, North CarolinaAges 18 years+ - NCT06892522RecruitingPhase 1/Phase 2
T cell therapies for multiple myeloma
This trial tests new antibody treatments for multiple myeloma, given alone or with other drugs. It aims to see if they can control the disease and what side effects might occur.
Charlotte, North CarolinaAges 18 years+ - NCT05722418RecruitingPhase 1
CRISPR-edited CAR-T for harder-to-treat myeloma
This Phase 1 study tests a lab-made immune cell therapy (CAR-T) made from a donor, with a CRISPR edit, for multiple myeloma that has come back or not responded to treatment. It aims to find the safest way to give the treatment and see how well it can control the cancer.
Charlotte, North CarolinaAges 18 years+ - NCT01351545Recruiting
Cryopreserved cord blood access program for transplant patients
This trial studies an organized way to obtain and distribute unlicensed (not FDA-approved for general use) stored cord blood units that have been frozen and kept. It may help people who need a cord blood transplant but don’t fit the “licensed cord blood only” options.
Charlotte, North CarolinaAges Any age - NCT05201781RecruitingPhase 4
Long-term follow-up for people previously treated with cilta-cel
This study follows people over time who previously received cilta-cel in a Janssen-sponsored clinical trial. It helps doctors learn about how well the treatment works and how safe it is in the long run.
Charlotte, North CarolinaAges 18 years+ - NCT05651932RecruitingPhase 1
Test of an MMSET inhibitor for relapsed multiple myeloma
This Phase 1 trial tests a new drug that targets MMSET in people whose multiple myeloma has returned or not responded to prior treatment. It aims to find a safe dose and see whether it can shrink myeloma in this setting.
Charlotte, North CarolinaAges 18 years+ - NCT06365060Recruiting
Screening for AL Amyloidosis in Smoldering Multiple Myeloma
This study is screening people with smoldering multiple myeloma or a monoclonal gammopathy to see if they might have an early form of AL amyloidosis, a condition where abnormal proteins build up in organs. If you meet the criteria, you will be tested to find out if you have amyloidosis, which could help catch it early.
Charlotte, North CarolinaAges 40 years+ - NCT05243797RecruitingPhase 3
Teclistamab plus lenalidomide maintenance after transplant
This trial tests whether adding teclistamab to lenalidomide (or using teclistamab alone) helps keep newly diagnosed multiple myeloma from coming back after an autologous stem cell transplant. It’s comparing these options to lenalidomide alone as long-term maintenance.
Charlotte, North CarolinaAges 18 years+ - NCT05332054Enrolling by invitation
Long-term follow-up after prior Caribou treatment
This study checks your health over time after you previously took a Caribou medicine (or got it through a special access program). It helps researchers learn what happens in the longer run after the treatment.
Charlotte, North CarolinaAges 18 years+ - NCT05652335RecruitingPhase 1
JNJ-79635322 for hard-to-treat myeloma or amyloidosis
This Phase 1 study tests how safe and how well JNJ-79635322 works in people with multiple myeloma that has come back or is resistant to treatment, or AL amyloidosis that has already been treated. It may help by targeting cancer cells and abnormal proteins driving these diseases.
Charlotte, North CarolinaAges 18 years+ - NCT05730036RecruitingPhase 3
Linvoseltamab vs standard treatment for relapsed myeloma
This trial compares linvoseltamab against a standard combination (elotuzumab + pomalidomide + dexamethasone) in adults with multiple myeloma that has returned or not responded. It aims to find out whether linvoseltamab works better and is safe for people who have already had some myeloma treatments.
Charlotte, North CarolinaAges 18 years+ - NCT05145400RecruitingPhase 2
Drug treatment for frail or older newly diagnosed multiple myeloma
This Phase 2 study tests whether “isa-Rd” can safely and effectively treat people who have newly diagnosed multiple myeloma and are frail or much older. It may help those who are at higher risk of side effects from stronger, full-intensity chemotherapy.
Charlotte, North CarolinaAges 18 years+ - NCT07391657RecruitingPhase 3
Comparing a new CAR-T therapy to standard treatments for multiple myeloma
This trial tests a new dual-targeted cell therapy (AZD0120) against standard regimens for people with multiple myeloma that has come back or not responded to treatment. It aims to see if the new therapy works better than standard options.
Charlotte, North CarolinaAges 18 years+ - NCT06615479RecruitingPhase 3
New treatment vs standard care for relapsed multiple myeloma
This trial tests a new treatment called BMS-986393 (a type of CAR T-cell therapy) compared to standard treatments for adults with multiple myeloma that has come back or is not responding to therapy, and who have already been treated with lenalidomide (Revlimid). The goal is to see if the new treatment works better.
Charlotte, North CarolinaAges 18 years+ - NCT07555938RecruitingPhase 3
New drug combination for previously treated multiple myeloma
This trial tests whether a new drug called cevostamab, combined with two existing myeloma drugs (pomalidomide and dexamethasone), works better than standard treatment for people whose myeloma has returned or stopped responding to prior therapy. You would receive this combination to see if it helps control your disease.
Charlotte, North CarolinaAges 18 years+ - NCT05828511RecruitingPhase 1/Phase 2
Study drug for newly diagnosed myeloma before standard treatment
This trial tests linvoseltamab (a new targeted immune treatment) to see if it’s safe and how well it works in adults with recently diagnosed multiple myeloma who haven’t started treatment yet. Because it’s a “window of opportunity” study, it’s meant to learn early results before standard therapy is fully underway.
Charlotte, North CarolinaAges 18 years+ - NCT06644625Recruiting
CHAAMP study: MGUS screening for Black adults and relatives
This study screens for MGUS, a precursor to certain blood cancers, in people who are Black or African American, or who have a close relative with a plasma cell disorder. If MGUS is found, you may be invited to continue in the study to monitor your health.
Charlotte, North CarolinaAges 30 years+
Hear when a new Multiple myeloma trial opens near Charlotte, NC
We’ll email you when one opens near Charlotte, NC — at most once a week, no account needed, unsubscribe anytime.
Multiple myeloma trials in other cities
Where these studies are running near Charlotte
Institutions with a site for the recruiting multiple myeloma studies listed above.
- Levine Cancer Institute · 9 studies
- Research Site · 3 studies
- Atrium Health Levine Cancer Institute · 2 studies
- Levine Cancer Center · 2 studies
- Novant Health · 2 studies
- Atrium Health Levine Cancer Institute /ID# 271510
- Atrium Health Levine Cancer Institute /ID# 276193
- Atrium Health Levine Children's Hospital
What taking part in a multiple myeloma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting multiple myeloma studies in North Carolina.
Common questions
- Are there multiple myeloma clinical trials near Charlotte?
- Yes. We're currently tracking 28 recruiting multiple myeloma studies with a site near Charlotte, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a multiple myeloma study near Charlotte?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Charlotte to take part?
- Not necessarily. These studies have a site near Charlotte, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a multiple myeloma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New multiple myeloma studies open near Charlotte regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.